CF
CMPX icon

Corebridge Financial’s Compass Therapeutics CMPX Stock Holding History

Corebridge Financial’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,963
Closed -$94.9K – 587
2025
Q1 		$94.9K Sell
49,963
-741
-1% -$1.97K ﹤0.01% 2466
2024
Q4 		$73.5K Sell
50,704
-3,828
-7% -$6.36K ﹤0.01% 2700
2024
Q3 		$100K Sell
54,532
-336
-0.6% -$419 ﹤0.01% 2616
2024
Q2 		$54.9K Buy
+54,868
New +$80.1K ﹤0.01% 2876

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corebridge Financial's CMPX Position: Q2 2025 in Review

Corebridge Financial sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 49,963 shares — an estimated $94.9K sold.

Corebridge Financial first reported a position in CMPX in Q2 2024 and held it in 4 quarters. The position peaked at $100K in Q3 2024. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

  • Corebridge Financial reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 49,963 Compass Therapeutics shares in Q2 2025, an estimated $94.9K.
  • Corebridge Financial first reported a position in Compass Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Compass Therapeutics position peaked at $100K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.